

.....  
(Original Signature of Member)

119TH CONGRESS  
1ST SESSION

**H. RES.** \_\_\_\_\_

Expressing support for the recognition of “Hidradenitis Suppurativa  
Awareness Week”.

\_\_\_\_\_  
**IN THE HOUSE OF REPRESENTATIVES**

Mrs. DINGELL submitted the following resolution; which was referred to the  
Committee on \_\_\_\_\_

\_\_\_\_\_  
**RESOLUTION**

Expressing support for the recognition of “Hidradenitis  
Suppurativa Awareness Week”.

Whereas Hidradenitis Suppurativa (in this resolution referred  
to as “HS”) is a chronic, inflammatory skin disease that  
affects approximately 3,300,000 people in the United  
States;

Whereas HS causes painful, boil-like nodules and abscesses  
anywhere on the body, and can progress to form tunnels  
under the skin and cause extensive scarring;

Whereas individuals with HS frequently suffer from 5 pri-  
mary domains of physical and emotional suffering, pain,  
drainage, odor, itching, and profound psychological dis-  
tress;

Whereas HS is associated with one of the highest completed suicide rates among dermatological diseases, second only to melanoma;

Whereas 75 percent of individuals with HS are misdiagnosed or not diagnosed until after age 25, missing critical windows for early intervention and care;

Whereas delayed diagnosis contributes to worsening disease progression, higher healthcare costs, avoidable emergency room visits, and unnecessary procedures;

Whereas individuals are often diagnosed with HS in the prime of their lives, affecting their ability to work, maintain relationships, and participate fully in society;

Whereas, as of June 1, 2025, there are only 3 biologic therapies approved by the Food and Drug Administration for the treatment of HS;

Whereas additional research is urgently needed to develop new treatments, understand the pathogenesis of the disease, identify biomarkers of HS, and improve outcomes for HS patients;

Whereas Federal policy can play a critical role in improving access to biologic therapies, wound care, and comprehensive care for HS patients; and

Whereas designating the first week of June as “Hidradenitis Suppurativa Awareness Week” would increase public awareness, foster understanding, and catalyze progress in diagnosing, treating, and ultimately curing HS: Now, therefore, be it

1       *Resolved*, That the House of Representatives—

2               (1) supports the recognition of “Hidradenitis

3       Suppurativa Awareness Week”; and

1 (2) recognizes the importance of—

2 (A) increasing awareness and education  
3 about HS among the public and health profes-  
4 sionals;

5 (B) promoting timely and accurate diag-  
6 nosis of HS through improved screening and  
7 culturally competent care;

8 (C) supporting biomedical research to bet-  
9 ter understand HS pathogenesis, treatment effi-  
10 cacy, and long-term outcomes;

11 (D) accelerating the development of effec-  
12 tive treatments and expanding access to exist-  
13 ing therapies for HS; and

14 (E) advancing policies that address dis-  
15 parities in access to care for patients with HS  
16 and improve the quality of life for individuals  
17 living with HS and the caregivers of such indi-  
18 viduals.